Form 4: Protara Therapeutics Director Acquires Stock Options

Protara Therapeutics Director Richard S. Levy acquired 31,000 stock options with an exercise price of $3.94, vesting on June 15, 2027.

Summary

• Richard S. Levy, a Director at Protara Therapeutics, Inc. (TARA), acquired 31,000 stock options on June 15, 2026.
• The options have an exercise price of $3.94 per share.
• These options are part of an annual grant and are set to vest in full on the first anniversary of the grant date, provided continuous service as a Board member.
• Vesting will also occur immediately upon a Change of Control.
• The options have an expiration date of June 14, 2036.
• Following this transaction, Levy beneficially owns 31,000 shares directly.

Sentiment

Score: 6

Explanation: StockSavvy.ai views this as a neutral to slightly positive filing, as it indicates a director's commitment and belief in the company's future through option acquisition, but it does not represent new capital for the company.

Positives

• Director's acquisition of stock options signals confidence in the company's future prospects.
• The stock options are exercisable at a price of $3.94, potentially offering significant upside if the stock price increases.
• Vesting upon Change of Control provides an incentive aligned with shareholder value in such an event.

Negatives

• The filing only details the acquisition of options, not the purchase of common stock, which could be seen as less direct investment.
• The exercise price of $3.94 indicates the current market price or a price close to it at the time of grant.

Risks

• The vesting of options is contingent on continuous service, meaning a departure from the board before the vesting date would result in forfeiture.
• The value of the options is directly tied to the future stock performance of Protara Therapeutics, which is subject to market volatility and company-specific risks.
• A Change of Control event, while triggering vesting, may also involve significant strategic shifts or potential disruptions for the company.

Future Outlook

The stock options acquired by Director Richard S. Levy are subject to vesting conditions, with full vesting expected on June 15, 2027, or upon a Change of Control. The options expire on June 14, 2036.

Industry Context

StockSavvy.ai notes that the acquisition of stock options by a director is a common practice in the biotechnology and pharmaceutical sectors, aligning management incentives with shareholder interests and reflecting a belief in the company's long-term growth potential.

Stakeholder Impact

• Shareholders: The acquisition of options by a director can be viewed positively, suggesting confidence in future stock performance. However, it does not directly inject capital into the company.
• Employees: The vesting conditions tied to continuous service may encourage employee retention.
• Management: Aligns the director's financial interests with the company's stock performance, particularly in the event of a Change of Control.

Next Steps

• Director Levy must maintain continuous service through June 15, 2027, for the options to vest.
• The company may experience a Change of Control event before June 15, 2027, which would trigger immediate vesting.
• The options will expire on June 14, 2036, if not exercised.

Key Dates

Keywords

Protara Therapeutics, TARA, Form 4, Stock Options, Director, Beneficial Ownership, SEC Filing, Equity Grant, Vesting, Change of Control